New Fundings And Goals To Match Raised In Latest MDUFA IV Session
This article was originally published in The Gray Sheet
Executive Summary
As the number of de novo applications and pre-submission consultations keep growing, FDA is proposing to institute provide new funding for these programs, among a range of additional proposals laid out in a recent closed-door negotiation. The agency's plan aligns somewhat with an industry proposal, according to meeting minutes, but there is also a lot to negotiate.
You may also be interested in...
Senate Seeks Performance Data From FDA On De Novos, Postmarket Surveillance
A Senate panel directs FDA to meets its statutory deadlines for de novo reviews and device risk classifications of devices, and requests data on those programs – as well as for the agency's postmarket device surveillance activities – in a 2017 appropriations bill.
MDUFA Negotiations Mellow Out Over Opposing Wish Lists
As FDA and industry struggle to align on reform priorities for a cost-conscious user-fee reauthorization proposal, the two sides took a step back to examine basic assumptions at a recent closed-door meeting.
User-Fee Sticker Shock? Industry Pursues Trimmed-Down MDUFA IV Proposal
Device industry groups significantly pared down their review-process reform proposals for the next user-fee program at a meeting with FDA last month. To lower the price tag, they expunged more than a dozen ideas that have been raised by companies or the agency at prior meetings. But FDA sees a lot of important priorities missing in industry's latest five-point plan.